pharmaceutical investing AMAG Pharmaceuticals Announces Topline Results From the PROLONG Trial Evaluating Makena
pharmaceutical investing AMAG Pharmaceuticals Acquires Orphan Drug Candidate for Treatment of Severe Preeclampsia
pharmaceutical investing AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration
pharmaceutical investing AMAG Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for Feraheme
pharmaceutical investing AMAG and Endoceutics Enter Into an Exclusive U.S. License Agreement for Intrarosa™ (Prasterone)
pharmaceutical investing AMAG Pharmaceuticals Announces Closing of Exclusive Licensing Agreement for North American Rights to Rekynda™
AMAG Pharmaceuticals Announces Achievement of Key Milestones in Next Generation Development Programs for Makena® and Feraheme®
QIMC Extends DDH-26-05 Drilling to Beyond 1,000 Metres and Launches In-Situ Hydrogen Characterization and Extraction Program at Bennett Hill as Seismic Further Corroborates Two Distinct Hydrogen Systems in Nova Scotia
CoTec Holdings Corp. Files Third Quarter Financial Statements and MD&A and Provides Market Commentary
